Ovid Therapeutics Files 8-K on Shareholder Nominations
Ticker: OVID · Form: 8-K · Filed: May 2, 2025 · CIK: 1636651
| Field | Detail |
|---|---|
| Company | Ovid Therapeutics Inc. (OVID) |
| Form Type | 8-K |
| Filed Date | May 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-nomination, sec-filing
TL;DR
Ovid Therapeutics filed an 8-K regarding shareholder nominations for board seats.
AI Summary
Ovid Therapeutics Inc. filed an 8-K on May 2, 2025, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the company is providing information related to shareholder proposals for its upcoming meeting.
Why It Matters
This filing is important for shareholders as it outlines the process and details regarding nominations for the board of directors, impacting corporate governance.
Risk Assessment
Risk Level: low — This is a routine procedural filing related to corporate governance and shareholder nominations, not indicating any immediate financial or operational risks.
Key Players & Entities
- Ovid Therapeutics Inc. (company) — Registrant
- May 1, 2025 (date) — Earliest event reported
- May 2, 2025 (date) — Date of report
- Exchange Act Rule 14a-11 (regulation) — Subject of the filing
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on shareholder nominations pursuant to Exchange Act Rule 14a-11.
What is the exact date of the earliest event reported in this filing?
The earliest event reported in this filing is dated May 1, 2025.
What is the filing date of this 8-K report?
This 8-K report was filed on May 2, 2025.
What is the company's exact name as specified in its charter?
The company's exact name as specified in its charter is Ovid Therapeutics Inc.
Under which section of the Securities Exchange Act is this report filed?
This Current Report is filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 2, 2025 regarding Ovid Therapeutics Inc. (OVID).